Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70391 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Masaya Tachibana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Long QT Syndrome, Hematologic Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi Sankyo Co. Ltd.
Abstract (Originalsprache)
This study assessed the potential risk of QT prolongation associated with the dual enhancer of zeste homolog 1/2 inhibitor valemetostat. An evaluation of the relationship between plasma valemetostat concentration and heart‐rate‐corrected QT (QTc) interval was performed. Time‐matched plasma concentration and 12‐lead electrocardiogram data were collected from the phase I studies DS3201‐A‐J101, in patients with relapsed/refractory B‐/T‐cell non‐Hodgkin lymphomas (NCT02732275), and DS3201‐A‐U102, in patients with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia (NCT03110354). A prespecified linear mixed‐effects model was used to assess the effect of valemetostat on change in QTc corrected by the Fridericia method (ΔQTcF). A population‐specific method (ΔQTcP) was also used to remove the heart rate interval (RR) dependence. The final dataset contained 769 electrocardiogram measurements from 100 patients. Linear mixed‐effects modeling found no significant demographic or clinical covariate effects. The slope versus concentration was significant (95% confidence interval [CI] of the coefficient excluded 0) in the final models for ΔQTcF, but not ΔQTcP, while the relative standard error of the slope was > 50% for both models. Baseline QTc had a negative effect on ΔQTc in all models. At the steady‐state geometric mean maximum concentrations in the dose range of 100–700 mg tested in the DS3201‐A‐J101 and DS3201‐A‐U102 studies, the 90% CI upper bounds for model‐predicted ΔQTcF and ΔQTcP were 1.52–8.38 ms, all of which were below the clinically significant threshold of 10 ms. The analysis supports a lack of a clinically meaningful effect on the QTc interval for valemetostat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
- Drug Development Solutions, Certara, Radnor, Pennsylvania, USA.
- Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
- Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.
ORCID-Profile: Masaya Tachibana, Bill Poland, Yasuyuki Kakurai, Claire Li, Yvonne Lau
Förderung
- Daiichi Sankyo Co. Ltd
Zitieren
APA
Tachibana, M., Poland, B., Kakurai, Y., Chen, Y., Li, C., & Lau, Y. (2025). Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies. Clinical and Translational Science. https://doi.org/10.1111/cts.70391
Vancouver
Tachibana M, Poland B, Kakurai Y, Chen Y, Li C, Lau Y. Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies. Clinical and Translational Science. 2025. doi:10.1111/cts.70391
BibTeX
@article{Tachibana2025,
author = {Tachibana, Masaya and Poland, Bill and Kakurai, Yasuyuki and Chen, Yang and Li, Claire and Lau, Yvonne},
title = {Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70391}
}
EUVIMED